Clinical trials: Rosuvastatin
Healthy
CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
The CYP2B6 enzyme metabolizes a growing number of clinically important drugs such as the anti-HIV drug efavirenz, but its activity in the liver is highly variable, which may lead to failure of therapy or toxicity and…
- Trial name
- NCT02401256
- Testing
- Efavirenz, Bupropion, Rosuvastatin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Indiana University
Hypercholesterolemia
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01507831
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 320 sites in United States, Argentina and 25 more
- Volunteers
- 2,341 people
- Sponsor
- Sanofi
Hypercholesterolemia
Open Label Study of Long Term Safety Evaluation of Alirocumab
Primary Objective: To assess the long-term safety of alirocumab (SAR236553/REGN727) when added to lipid-lowering therapy in participants with heterozygous familial hypercholesterolemia (heFH) who had completed EFC12492…
- Trial name
- ODYSSEY OLE (NCT01954394)
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 177 sites in United States, Argentina and 22 more
- Volunteers
- 986 people
- Sponsor
- Sanofi
Hypercholesterolemia With Concomitant Type 2 Diabetes
LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
The purpose of this study is to compare the effect of rosuvastatin and atorvastatin on lipid lowering effect and glucose metabolism in hypercholesterolemia patients with diabetes mellitus.
- Trial name
- LISTEN (NCT01544309)
- Testing
- Atorvastatin, Rosuvastatin
- Where
- 133 sites in Japan
- Volunteers
- 1,049 people
- Sponsor
- Listen Trial Group
Healthy, Obese
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that…
- Conditions
- Healthy, Obese, Overweight
- Trial name
- NCT06186622
- Testing
- Orforglipron, Simvastatin, Digoxin
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Coronary Atherosclerosis
CRESTOR Athero Imaging Head to Head IVUS Study
A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular…
- Trial name
- SATURN (NCT00620542)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 195 sites in United States, Argentina and 12 more
- Volunteers
- 2,333 people
- Sponsor
- AstraZeneca
Cardiovascular Disease
CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction
Background: Coronary artery disease causes plaque in arteries. This can cause stroke or heart disease. Drugs called statins might shrink plaque.
- Trial name
- NCT02740699
- Testing
- Rosuvastatin, Atorvastatin, Cardiac Computed Tomography (CT)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pharmacokinetics, Healthy Volunteers
A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
The purpose of this study is to learn about the effect of the study medicine (called nirmatrelvir/ritonavir) on the pharmacokinetics of the medicine rosuvastatin in healthy volunteers.
- Trial name
- NCT05898672
- Testing
- Rosuvastatin, Nirmatrelvir/ritonavir
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia, Dyslipidemia
A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins
PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.
- Trial name
- NCT01350141
- Testing
- PF-04950615 (RN316)
- Where
- 35 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Pfizer
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Hypertension,, Hyperlipidemia
Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and…
- Trial name
- NCT01918332
- Testing
- Valsartan 160mg, Rosuvastatin 20mg
- Where
- South Korea
- Volunteers
- 168 people
- Sponsor
- LG Life Sciences
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- ODYSSEY FH I (NCT01623115)
- Testing
- Alirocumab, Lipid Modifying Therapy (LMT)
- Where
- 91 sites in United States, Austria and 12 more
- Volunteers
- 486 people
- Sponsor
- Sanofi
Dyslipidemia
Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
The purpose of the study is to show the compliance rates of the patients to statin treatment and the reasons of non-compliance.
- Trial name
- NCT00673660
- Testing
- Patient Compliance
- Where
- 5 sites in Turkey (Türkiye)
- Volunteers
- 375 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
A Study Comparing CoQ10 Levels While Taking 3 Different Statins
The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than Atorvastatin or Rosuvastatin.
- Trial name
- SPARQ (NCT01660191)
- Testing
- Pitavastin 4mg, Atorvastatin 20mg, Rosuvastatin 5mg
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- University of Kansas Medical Center